Pegylated recombinant human endostatin - SShandong Simcere Medgenn

Drug Profile

Pegylated recombinant human endostatin - SShandong Simcere Medgenn

Alternative Names: Endu-PEG; PEG-Endostar injection; Pegylated Endostar injection; SIM-0710

Latest Information Update: 05 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shandong Simcere Medgenn Bio-Pharmaceutical
  • Developer China Pharmaceutical University; Shandong Simcere Medgenn Bio-Pharmaceutical
  • Class Angiostatic proteins; Antineoplastics; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Aug 2015 Preclinical trials in Cancer in China (IV)
  • 31 Mar 2010 Early research in Cancer in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top